SE456316B - Steril, isoton vattenlosning med plasmaexpanderande verkan, innehallande ett raffinerat pullulan, samt forfarande for framstellning derav - Google Patents
Steril, isoton vattenlosning med plasmaexpanderande verkan, innehallande ett raffinerat pullulan, samt forfarande for framstellning deravInfo
- Publication number
- SE456316B SE456316B SE8003850A SE8003850A SE456316B SE 456316 B SE456316 B SE 456316B SE 8003850 A SE8003850 A SE 8003850A SE 8003850 A SE8003850 A SE 8003850A SE 456316 B SE456316 B SE 456316B
- Authority
- SE
- Sweden
- Prior art keywords
- pullulan
- refined
- pul
- plasma
- molecular weight
- Prior art date
Links
- 229920001218 Pullulan Polymers 0.000 title claims description 89
- 235000019423 pullulan Nutrition 0.000 title claims description 89
- 239000004373 Pullulan Substances 0.000 title claims description 82
- 238000000034 method Methods 0.000 title claims description 21
- 230000000694 effects Effects 0.000 title claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 11
- 239000000203 mixture Substances 0.000 claims description 47
- 238000002360 preparation method Methods 0.000 claims description 45
- 239000007864 aqueous solution Substances 0.000 claims description 20
- 238000009826 distribution Methods 0.000 claims description 16
- 239000002504 physiological saline solution Substances 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 7
- 239000000644 isotonic solution Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 150000004676 glycans Chemical class 0.000 description 30
- 229920001282 polysaccharide Polymers 0.000 description 30
- 239000005017 polysaccharide Substances 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000011534 incubation Methods 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 239000003058 plasma substitute Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 11
- 238000005534 hematocrit Methods 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 101150039167 Bex3 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100001021 decreased hematocrit Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP54063976A JPS6049164B2 (ja) | 1979-05-25 | 1979-05-25 | 血漿増量剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8003850L SE8003850L (sv) | 1980-11-26 |
| SE456316B true SE456316B (sv) | 1988-09-26 |
Family
ID=13244813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8003850A SE456316B (sv) | 1979-05-25 | 1980-05-22 | Steril, isoton vattenlosning med plasmaexpanderande verkan, innehallande ett raffinerat pullulan, samt forfarande for framstellning derav |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4370472A (en, 2012) |
| JP (1) | JPS6049164B2 (en, 2012) |
| DE (1) | DE3019895A1 (en, 2012) |
| FR (1) | FR2458286A1 (en, 2012) |
| GB (1) | GB2052975B (en, 2012) |
| IT (1) | IT1130734B (en, 2012) |
| SE (1) | SE456316B (en, 2012) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2517326B1 (fr) * | 1981-12-01 | 1989-09-01 | Hayashibara Biochem Lab | Production d'une preparation de pullulane a repartition etroite de masses moleculaires |
| US4913925A (en) * | 1982-10-25 | 1990-04-03 | Yasutake Hiji | Foodstuff containing a hyperglycemia controlling agent |
| JPS5974976A (ja) * | 1982-10-25 | 1984-04-27 | Yasutake Hichi | 血糖値上昇抑制剤を添加した飲食物 |
| JPS62236469A (ja) * | 1986-04-04 | 1987-10-16 | Yasutake Hichi | 低カロリ−飲食物 |
| US6746836B1 (en) * | 2000-12-08 | 2004-06-08 | Abe Widra | Alpha-keratose as a blood plasma expander and use thereof |
| US10130587B2 (en) | 2011-01-11 | 2018-11-20 | Capsugel Belgium Nv | Hard capsules |
| US11319566B2 (en) | 2017-04-14 | 2022-05-03 | Capsugel Belgium Nv | Process for making pullulan |
| ES3033915T3 (en) | 2017-04-14 | 2025-08-11 | Capsugel Belgium Nv | Pullulan capsules |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1096850B (de) * | 1959-07-24 | 1961-01-12 | Hoechst Ag | Verfahren zur Gewinnung eines dextranaehnlichen Polysaccharids aus Pullularia pullulans |
| JPS5142199B2 (en, 2012) * | 1972-09-04 | 1976-11-13 |
-
1979
- 1979-05-25 JP JP54063976A patent/JPS6049164B2/ja not_active Expired
-
1980
- 1980-05-21 US US06/152,151 patent/US4370472A/en not_active Expired - Lifetime
- 1980-05-22 SE SE8003850A patent/SE456316B/sv not_active IP Right Cessation
- 1980-05-23 IT IT22285/80A patent/IT1130734B/it active
- 1980-05-23 FR FR8011531A patent/FR2458286A1/fr active Granted
- 1980-05-23 DE DE19803019895 patent/DE3019895A1/de active Granted
- 1980-05-27 GB GB8017288A patent/GB2052975B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE8003850L (sv) | 1980-11-26 |
| US4370472A (en) | 1983-01-25 |
| JPS55157513A (en) | 1980-12-08 |
| GB2052975A (en) | 1981-02-04 |
| IT8022285A0 (it) | 1980-05-23 |
| FR2458286A1 (fr) | 1981-01-02 |
| JPS6049164B2 (ja) | 1985-10-31 |
| DE3019895C2 (en, 2012) | 1987-10-29 |
| DE3019895A1 (de) | 1980-11-27 |
| FR2458286B1 (en, 2012) | 1983-11-04 |
| GB2052975B (en) | 1983-09-07 |
| IT1130734B (it) | 1986-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morita et al. | Nail-patella syndrome: Light and electron microscopic studies of the kidney | |
| Whipple et al. | Fibrinogen of the blood as influenced by the liver necrosis of chloroform poisoning | |
| Kurrein | Cerebral mucormycosis | |
| SE456316B (sv) | Steril, isoton vattenlosning med plasmaexpanderande verkan, innehallande ett raffinerat pullulan, samt forfarande for framstellning derav | |
| Crocker et al. | Developmental defects of the kidney: a review of renal development and experimental studies of maldevelopment | |
| CN113440532A (zh) | 一种褐藻寡糖的应用 | |
| Barnard, PJ & Kibel | The haemolytic-uraemic syndrome of infancy and childhood: a report of eleven cases | |
| DE2459915B2 (de) | Aktive Verbindung des Plasminogen-Typs, Verfahren zu ihrer Reinigung und ihre Verwendung | |
| Rimington et al. | Studies upon the photosensitisation of animals in South Africa X: the icterogenic factor in geeldikkop: isolation of active principles from Lippia rehmanni Pears | |
| DE2734150A1 (de) | Verfahren zur gewinnung von human- lysozym | |
| DE2605576C3 (de) | Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
| Willcox | Toxic jaundice | |
| Grossman et al. | Effect of heparin on fate of intravenously administered fat emulsions in rats. | |
| US4024247A (en) | Composition and method of using a protein mixture derived from liver | |
| Wynn et al. | Chromatographic observations on nitrogenous constituents of petroleum-ether extracts of plasma | |
| DE2409650C3 (de) | Verwendung wäßriger Lösung von menschlichem Serum-Haptoglobin bei der Bekämpfung von hämolytischen Nierenstörungen | |
| US2143475A (en) | Therapeutic agent | |
| JP3769045B2 (ja) | 抗炎症剤 | |
| Evans | Anaemia associated with the sickle cell trait in British West African natives | |
| Gadd, KG, Nixon, LC, Taube, E. & Webster | The Lusito tragedy | |
| JP2889491B2 (ja) | 血圧降下剤 | |
| DE1617279A1 (de) | Verfahren zur Herstellung pharmazeutischer Praeparate zur Verhinderung der Bildung von Blutgerinnseln | |
| Coimbra et al. | Effect of urinary alkalinization on renal changes produced by cationic albumin | |
| JP2005532992A (ja) | 肝炎治療剤及び予防剤または肝臓保護剤として有用なソムオガルピ（ＡｃａｎｔｈｏｐａｎａｘＫｏｒｅａｎｕｍ）抽出物 | |
| DE1767099B1 (de) | Verfahren zur Gewinnung eines Glykoproteins mit einer Hemmwirkung gegenueber Magensaeureabsonderung und einer Antiaktivitaet gegenueber Ulcus-Bildung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8003850-8 Effective date: 19911209 Format of ref document f/p: F |